Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Alzheimers Dement. 2023 Mar 30;19(10):4651–4661. doi: 10.1002/alz.13036

Table 2.

Sex-specific associations between APOE ε2 (vs APOE ε3/ε3) and longitudinal cognition in non-Hispanic White participants.

Analyses Sample 1 (NACC &
ROS/MAP)
NACC ROS/MAP Sample 2 (ADNI &
Prevent-AD)
β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p
Three-way interaction:
   Sex × APOE ε2 (vs. ε3/ε3) × time 0.097 (0.023 – 0.172) .01 0.081 (0.010 – 0.152) .02 0.127 (−0.069 – 0.323) .20 0.195 (0.006 – 0.385) .04
Sex-stratified two-way interactions:
   APOE ε2 (vs. ε3/ε3) × time in men 0.096 (0.037 – 0.155) .001 0.074 (0.020 – 0.128) .008 0.149 (−0.022 – 0.319) .09 0.093 (−0.056 – 0.243) .22
   APOE ε2 (vs. ε3/ε3) × time in women −0.001 (−0.044 – 0.043) .97 −0.008 (−0.051 – 0.035) .71 0.012 (0.089 – 0.114) .81 −0.104 (−0.228 – 0.020) .10
Genotype-stratified two-way interaction:
   Male sex × time in APOE ε2 carriers 0.120 (0.051 – 0.190) .001 0.095 (0.028 – 0.161) .005 0.191 (0.012 – 0.371) .04 0.160 (−0.002 – 0.321) .05
   Male sex × time in APOE ε3/ε3 carriers −0.000 (−0.031 – 0.030) .99 −0.005 (−0.033 – 0.024) .75 0.038 (−0.044 – 0.121) .36 −0.009 (−0.091 – 0.074) .84

NACC: National Alzheimer’s Coordinating Center

ROS: Religious Orders Study

MAP: Memory Aging Project

ADNI: Alzheimer’s Disease Neuroimaging Initiative

Prevent-AD: Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease

CI: confidence interval